Committee:

List targets based on DNA/RNA analysis that may be treated by FDA-approved drugs either in an on-label or off-label manner based on peer-reviewed clinical data; List findings that suggest a particular targeted therapy which the physician would otherwise use may not work due to a potential resistance marker; ................
................